225 related articles for article (PubMed ID: 16601374)
1. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
2. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
3. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
[TBL] [Abstract][Full Text] [Related]
4. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
5. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
6. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
7. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
8. Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.
Lüftner D; Possinger K
Onkologie; 2005 Nov; 28(11):595-602. PubMed ID: 16249646
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
10. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
11. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
Tuffaha HW; Treish IM; Zaru L
J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
[TBL] [Abstract][Full Text] [Related]
12. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
Pérez Velasco R
J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
[TBL] [Abstract][Full Text] [Related]
13. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
Khan S; Dhadda A; Fyfe D; Sundar S
Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
[TBL] [Abstract][Full Text] [Related]
14. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
15. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors for febrile neutropenia].
Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
[TBL] [Abstract][Full Text] [Related]
18. Prechemotherapy assessment of neutropenic risk.
Doyle AM
Oncology (Williston Park); 2006 Sep; 20(10 Suppl Nurse Ed):32-9; discussion 39-40. PubMed ID: 18153977
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.
Rofail P; Tadros M; Ywakim R; Tadrous M; Krug A; Cosler LE
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):699-709. PubMed ID: 23252353
[TBL] [Abstract][Full Text] [Related]
20. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
Adams JR; Angelotta C; Bennett CL
J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
